Replies to post #13654 on CytoSorbents Corporation (CTSO)

[orangecat]

There is really not enough details in this abstract to draw a conclusion. It says that the adsorber did not significantly decrease plasma free hemoglobin resulting for hemolysis. However, we know Cytosorb adsorption rates are concentration dependent and we don't know if the patient population had hemoglobin levels high enough to even need significant reduction. We also don't know the circuit setup with Cytosorb. Note that REFRESH 2 is using a dual adsorber setup. The abstract also does say that statistically significant differences in the median levels of haptoglobin and lactate dehydrogenase.

In REFRESH 2 hemoglobin reduction is also a secondary endpoint. Primary is reduction in incidents of AKI.